Previous 10 | Next 10 |
Revenues excluding Covid test sales increased 15% for fiscal 2023 vs fiscal 2022 Successfully completed inFoods ® IBS pilot program with one of the largest Gastrointestinal physician groups in the US inFoods IBS completes pre-launch phase; Veteran VP of sales ...
2023-08-03 12:22:06 ET More on Biomerica Biomerica stock rises on approval of colorectal, breast screening tests in Saudi Arabia, UAE Amazon starts selling Biomerica's Aware Breast Self Exam device, EZ Detect test Biomerica stock jumps after Walmart to begin selling ...
Over 7,000 CVS Pharmacy Stores to sell the EZ Detect ™ Test Simple 2 minute at-home test detects an early warning sign of colorectal cancer IRVINE, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced...
Patent Claims Describe a Novel System to Predict and Help Prevent Adverse Food Reactions Using Personal Medical Data The Patent further describes Algorithms to help Determine Safety Levels of Food Ingredients, Offering a Personalized Approach to Dietary Interventions and Safety ...
2023-05-19 12:49:26 ET Gainers: Mallinckrodt ( MNK ) +251% . Biocept ( BIOC ) +47% . WISeKey International Holding ( WKEY ) +41% . Aemetis ( AMTX ) +33% . Crescera Capital Acquisition ( CREC ) +32% . Stereotaxis ( STXS ) ...
Gastro Health, a leading gastroenterology group, plans to utilize this simplified blood collection method when recommending the inFoods ® IBS to their patients Biomerica also announced that inFoods ® IBS clinical trial data was presented at the DDW co...
Gastro Health is a leading gastroenterology group with over 380 GI physicians in the United States Clinical study results show patients who eliminated foods as determined by the inFoods® IBS test experience significant improvement in IBS Symptoms Including Abdominal Pain Intensity ...
For the nine months ended February 28, 2023 vs. the same period in 2022, revenues, excluding sales of Covid-related products, increased by 16%. InFoods ® IBS Laboratory Developed Test (LDT) validation testing at the CLIA Lab has been completed, patient testing now underway. IRV...
InFoods ® IBS LDT validation testing at the CLIA Lab is completed and the product is now being offered commercially Clinical trial data shows InFoods ® IBS treatment diet significantly improved several key IBS symptoms including Abdominal Pain Intensity (API)...
IRVINE, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) (“Biomerica”), a global provider of advanced medical products, announced today the closing of its previously announced underwritten public offering of an aggregate of 3,333,333 shares of its common sto...
News, Short Squeeze, Breakout and More Instantly...
inFoods ® IBS patients can now conveniently self-collect a blood sample using a simple finger-stick methodology in the privacy of their home inFoods ® IBS test is the first of its kind to identify specific foods that can trigger an Irritable Bowel Syndrome (I...
Biomerica (NASDAQ: BMRA) , a biomedical technology company that develops, patents, manufactures and markets advanced diagnostics and therapeutic products, has entered into an at-market issuance sales agreement with EF Hutton LLC and R.F. Lafferty & Co. Inc. According to the company, the agree...
With IBS affecting 10 to 15% of the global population, the associated $21 billion in direct medical costs and absenteeism underscores the urgent need of innovative solutions. Recognized as the 7th most common diagnosis by all physicians, IBS represents a significant healthcare burden. inF...